Avtor/Urednik		Fettich, J; Padhy, A; Nair, N; Morales, R; Tanumihardija, M; Riccabonna, G; Nair, G
Naslov		Comparative clinical efficacy and safety of phosphorus-32 and strontium-89 in the palliative treatment of metastatic bone pain: results of an IAEA coordinated research project
Tip		članek
Vir		World J Nucl Med Print
Vol. in št.		Letnik 2, št. 3
Leto izdaje		2003
Obseg		str. 226-31
Jezik		eng
Abstrakt		The aim of the study was to evaluate safety and efficacy of P-32 for palliation of bone pain due to bony metastases by comparing it wish Sr-89 in the framework of a prospective IAEA co-ordinated multi-centric study, Ninety-three patients with osteoblastic bony metastases were included in the study, 48 were treated with Sr-89 and 45 with P-32. Pain score, analgesic consumption, guality of life, and indices of bone marrow depression were monitored 2 weeks pre- and up to 4 months post treatment. Favourable response to treatment was recorded in 75% of the patients treated with Sr-89 and in 60% of those treated with P-32 (p=0.122, non-significant). There was no significant difference between the duration of favourable effect for both radiopharmaceuticals. Moderate decrease of white blood cell and platelet counts, and haemoglobin levels was detected in both the groups, but more often in the P-32 treated group. Although P-32 appeared to be a little more toxic than Sr-89, no toxic effects reguiring specific treatment were seen in either, group. Due to its comparable efficacy and safety combined with general availability and low cost, more widespread use of P-32 should be encouraged to enhance quality of life and reduce cost of medical care of patients with intractable metastatic bone pain.
Deskriptorji		BONE NEOPLASMS PAIN PHOSPHORUS RADIOISOTOPES STRONTIUM RADIOISOTOPES TREATMENT OUTCOME